Helicobacter pylori eradication in clinical practice: One-week low-dose triple therapy is preferable to classical bismuth based triple therapy

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 6, 1996, Pages 1009-1013

  Goddard, A F ^a   Spiller, R C ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; OMEPRAZOLE; TETRACYCLINE; TINIDAZOLE;

ARTICLE; BACTERIAL INFECTION; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERANCE; HELICOBACTER PYLORI; HUMAN; PRIORITY JOURNAL;

EID: 0029840245     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1996.95267000.x     Document Type: Article

References (16)

1. NIH, Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65-9.
2. Penston JG. Helicobacter pylori eradication - understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994; 8: 369-89.
3. Chiba N, Rao BV, Rademaker JW, Hunt RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992; 87: 1716-27.
4. Goddard A, Logan R. One-week low-dose triple therapy: new standards for Helicobacter pylori treatment Eur J Gastroenterol Hepatol 1995; 7: 1-3.
5. van der Hulst RWM, Keller JJ, Rauws EAJ, Tytgat GNJ. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1996; 1: 6-19.
6. McAlindon ME, Taylor J, Ryder SD. H. pylori eradication for bleeding duodenal ulcer by non-gastroenterologists: an audit. Gut 1995; 36 (Suppl. 1): A35 (Abstract).
7. Labenz J, Gyenes E, Ruhl GH, Borsch G. Amoxycillin plus omeprazole vs. triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized and controlled study. Gut 1993; 34: 1167-70.
8. Penston JG, Mistry KR. Eradication of H. pylori in general practice. Aliment Pharmacol Ther 1996; 10: 139-46.
9. Reilly TG, Ayres RCS, Poxon V, Walt RP. Helicobacter pylori eradication in a clinical setting: success rates and the effect on the quality of life in peptic ulcer. Aliment Pharmacol Ther 1995; 9: 483-90.
10. Glupczynski Y, Burette A. Drug therapy for Helicobacter pylori infection: problems and pitfalls. Am J Gastroenterol 1990; 85: 1545-51.
11. Karim QN, Logan RPH. The epidemiology of Helicobacter pylori (H. pylori) antimicrobial resistance - preliminary findings of a national survey. Gut 1995; 37, Suppl 2: A6 (Abstract).
12. Bell GD, Powell K, Burridge SM, et al. Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment isolate for metronidazole resistance. Aliment Pharmacol Ther 1992; 6: 427-36.
13. Lerang F, Moum B, Haug JB, et al. Highly effective twice a day triple therapies for Helicobacter pylori infection and peptic ulcer disease - metronidazole resistance is only of minor importance. Gastroenterology 1996; 110: A173 (Abstract).
14. Peitz U, Nusch A, Tillenberg B, et al. Frequent metronidazole resistance without significant impact on the high cure rate of Helicobacter pylori (HP) infection by triple therapy with omeprazole (OM), metronidazole (MET) and clarithromycin (CLA). Gastroenterology 1996; 110: A226 (Abstract).
15. Moayyedi P, Sahay P, Tompkins DS, Axon ATR. Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimenn to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol 1995; 7: 835-40.
16. Moayyedi P, Axon ATR. Patient factors that predict failure of omeprazole, clarithromycin and tinidazole (OCT) to eradicate Helicobacter pylori (H. pylori). Gut 1995; 36 (Suppl. 1): A46 (Abstract).